Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01101100 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis
A Phase 2 study, sponsored by Bausch Health Americas.
- Terminated
- Registry status
- Phase 2
- Development phase
- 181
- Enrollment target
NCT01101100 is a Phase 2 study that was terminated before completion, run by Bausch Health Americas. The registered enrollment target is 181 participants.
The verdict
NCT01101100, a Phase 2 study, was terminated before completion, sponsored by Bausch Health Americas.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 181 participants
- Enrollment target
Study Summary
This study is an open-label extension of study 20090062 to evaluate extended subcutaneous dosing.
Interventions
- DRUG AMG 827
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2010-04 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01101100
The ClinicalTrials.gov registry entry for NCT01101100 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 181 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMG 827 is the first listed.
NCT01101100 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01101100 about?
NCT01101100 is a clinical study titled "Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis". This study is an open-label extension of study 20090062 to evaluate extended subcutaneous dosing.
What is the current status of trial NCT01101100?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 181 participants. The study started on 2010-04. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01101100?
The interventions under investigation include: AMG 827 (DRUG).
Who is sponsoring clinical trial NCT01101100?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.